Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $48.85 Consensus Target Price from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned an average rating of “Buy” from the fifteen research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $48.85.

Several equities analysts have recently issued reports on the company. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Scotiabank assumed coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC lifted its holdings in shares of Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Dyne Therapeutics by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock valued at $173,808,000 after purchasing an additional 566,146 shares in the last quarter. RTW Investments LP lifted its holdings in shares of Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares in the last quarter. RA Capital Management L.P. lifted its holdings in shares of Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after purchasing an additional 440,890 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

DYN opened at $12.40 on Friday. Dyne Therapeutics has a 52-week low of $11.18 and a 52-week high of $47.45. The stock has a market capitalization of $1.40 billion, a PE ratio of -3.48 and a beta of 1.11. The stock’s 50 day moving average price is $13.89 and its 200-day moving average price is $24.58.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. Research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.